**Data supplement for**

**Genetic heterogeneity and subtypes of major depression**

Thuy-Dung Nguyen1,2; Arvid Harder1; Ying Xiong1; Kaarina Kowalec1,3; Sara Hägg1; Na Cai4, Ralf Kuja-Halkola1; Christina Dalman2; Patrick F Sullivan1,5; Yi Lu1,2

1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
2. Department of Global Public Health, Karolinska Institute, Stockholm, Sweden
3. College of Pharmacy, University of Manitoba, Winnipeg, Canada
4. Helmholtz Pioneer Campus, Helmholtz Zentrum München, Neuherberg, Germany
5. Department of Genetics and Psychiatry, University of North Carolina, Chapel Hill, NC, USA

Table of Contents

[I. SUPPLEMENTARY METHODS 2](#_Toc57409366)

[S1.1 Materials 2](#_Toc57409367)

[**UKB cohort** 2](#_Toc57409368)

[**MD case definitions** 2](#_Toc57409369)

[**MD subtypes** 2](#_Toc57409370)

[S2.2 Statistical analysis 3](#_Toc57409371)

[**Genome-wide association studies (GWAS)** 3](#_Toc57409372)

[**SNP-Heritability** 3](#_Toc57409373)

[**Genetic correlation** 4](#_Toc57409374)

[**Sensitivity analyses** 4](#_Toc57409375)

[II. SUPPLEMENTARY TABLES 5](#_Toc57409376)

[Table S2.1 Method to derive of MD cases, control and exclusion criteria in UKB 5](#_Toc57409377)

[Table S2.2 MD definitions and derived subtypes 9](#_Toc57409378)

[Table S2.3 Method to derive MD subtypes in UKB data 10](#_Toc57409379)

[Table S2.4 Medication list 13](#_Toc57409380)

[Table S2.5 Prevalence of subtypes to convert *h2g*from observed to liability scale 15](#_Toc57409381)

[Table S2.6 Significant loci in MD subtypes and broad MD phenotype GWAS 17](#_Toc57409382)

[Table S2.7 SNP-heritability and genetic correlation for subtypes within CIDI-SF MD cases 21](#_Toc57409383)

[III. SUPPLEMENTARY FIGURES 22](#_Toc57409384)

[S3.1 Included sample of study 22](#_Toc57409385)

[S3.2 SNP- heritability for MD definitions in UKB 23](#_Toc57409386)

[REFERENCEES 24](#_Toc57409387)

1. **SUPPLEMENTARY METHODS**

## **S1.1 Materials**

### **UKB cohort**

All UKB participants were invited to one of the assessment centers and answered touchscreen questionnaires that contains a section about mental health, followed by an interview with a research nurse where more details about mental illness and medication use were obtained. Psychiatric disorders diagnosed by clinicians were obtained from hospital admission records. Additionally, ~158,000 participants completed a web-based mental health questionnaire (MHQ) which is based on the Composite International Diagnostic Interview (CIDI).

### **MD case definitions**

The broad MD phenotype in this study is a composition of five MD definitions, including:

1. Lifetime depression based on the CIDI Short Form, i.e., lifetime depression according to the DSM-V criteria;
2. ICD-coded depression, i.e., any primary or secondary clinical diagnosis of major depressive disorder from linked hospital admission records;
3. Probable MD, i.e., presence of low mood or anhedonia for ≥2 weeks and ‘help-seeking’;
4. Self-reported MD, i.e., those self-reported having MD during nurse interview or mental health problems ever diagnosed by a professional as part of MHQ;
5. MD cardinal symptoms, i.e., ever had prolonged loss of interest in normal activities; or prolonged feelings of sadness or depression.

See *Supplementary table S2.1* about how to derive the MD definitions from UKB data

### **MD subtypes**

See *Supplementary table S2.3* for methods to derive subtypes in UKB data.

MD with atypical features versus non-atypical features. Symptoms of MD were extracted from the MHQ online follow-up, and used to determine if the participant had atypical features versus non-atypical features. As in a previous study(1), we defined MD with atypical features subtype as MD cases who reported both hypersomnia (UKB field: 20534) and weight gain (UKB field: 20536), and the others were non-atypical MD subtype.

Severe versus mild/moderate MD. The subtypes on symptom severity compared the cases with mild/moderate versus severe symptoms. Mild/moderate MD included those with probable recurrent MD (moderate) defined by Smith et al.(2) (UKB field: 20126), and/or ICD-diagnoses of mild (F320, F330) or moderate depression episode (F321, F331) (UKB field: 41202, 41204). Severe MD included probable recurrent MD (severe) defined by Smith et al.(2) (UKB field: 20126); and/or ICD-diagnoses of severe MD (F322, F323, F332, F333) (UKB field: 41202, 41204).

MD with or without comorbid anxiety disorder. The MD subtypes with or without comorbid anxiety disorder were defined using both self-reported and ICD-coded diagnoses. Participants of the MHQ reported mental health problems diagnosed by a professional (UKB 20544). Among the MD cases, we defined the subtype with comorbid anxiety disorder as those who also reported social anxiety/phobia, panic attacks, and anxiety, nerves/generalized anxiety disorder in the MHQ, and/or those with ICD diagnoses (UKB field: 41202, 41204) of anxiety disorder (F40, F41). For comparison, MD without comorbid anxiety disorder included MD cases with neither self-reported nor ICD-codes anxiety disorder.

Early versus late onset MD. Among >89,000 participants who answered the MHQ online follow-up, those who had MD cardinal symptoms reported the age at which they first experienced a ≥2-week episode (UKB field: 20433). Similar to previous studies(3, 4), we categorized the continuous variable of age at onset into octiles, then grouped the first 3 octiles into early-onset subtype (age onset ≤30) and the last 3 octiles into late-onset subtype (age onset ≥44).

Recurrent versus single-episode MD. Recurrent MD subtype was defined as those with probable recurrent MD defined by Smith et al. (2013)(2) (UKB field: 20126), and/or with ≥2 episodes of at least two weeks of cardinal symptoms (UKB field: 20442)(5), and/or ICD-diagnosis of recurrent MD (F33). Single-episode subtype included probable MD cases with one episode of feeling depressed (UKB field: 20126), and/or those self-reported a single episode (UKB field: 20442)(5), and/or ICD-diagnosis of non-recurrent MD (F32).

MD with or without suicidality. The subtype MD with suicidal thoughts included those who had reported thoughts of death during worst depression (UKB field: 20437); and/or those with recent thoughts of suicide or self-harm (UKB field: 20513). Non-suicidal subtype included MD cases who did not report suicidal thoughts.

MD with mild, moderate, severe impairment. Individuals who reported cardinal symptoms of MD were asked about the impact of MD on normal roles, including study/employment, childcare and housework, leisure pursuits, during the worst period of depression (UKB field: 20440). We categorized ‘not at all/a little impact’ as mild impairment, ‘somewhat’ as moderate impairment and ‘a lot’ as severe impairment.

Postpartum depression (PPD) cases were identified from three sources: women who reported post-natal depression during the nurse interview at the baseline recruitment (UKB field: 20002, code 1531); cases with MD cardinal symptoms related to childbirth (UKB field: 20445); and women with ICD diagnosis of mental and behavioral disorders associated with the puerperium (F53 in UKB fields: 41202, 41204).

## **S2.2 Statistical analysis**

### **Genome-wide association studies (GWAS)**

For GWAS, we constructed a genetic relationship matrix (GRM) for all UKB individuals of European ancestries based on 575,805 LD-pruned HapMap3 variants (LD-pruning parameters in PLINK 1.9: window size = 1Mb, step size = 100, r2 = 0.9). From a full GRM, we derived a sparse GRM by setting all elements <0.05 to 0 (--grm-sparse flag in GCTA). We then conducted case-control GWAS for each subtype using fastGWA, adjusting for sex, age, and the first 10 PCs.(6) Summary statistics were available for ~9.7 million common variants in each GWAS after filtering out those with low imputation quality (INFO<0.6).

### **SNP-Heritability**

We used linkage disequilibrium score regression (LDSC)(7) to estimate SNP-heritability (*h2*SNP) on the observed scale for each MD subtype. LDSC estimates SNP-heritability by regressing GWAS summary statistics on LD scores estimated from a reference population. We used LD scores from the European samples in the 1000 genomes reference panel. To allow comparison between subtypes, we converted SNP-heritability from the observed to the liability scale, and as previously suggested(8), we corrected for oversampling and extreme phenotype selection using sample prevalence, population case and control prevalence (details in Supplementary table S2.5).

The conversion of SNP-heritability from observed to liability scale was based on Yap et al. (2018)(8), formula 1, *Supplementary method.*

### **Genetic correlation**

Genetic correlations (*rg*) were estimated using a recent extension of LDSC, High-Definition Likelihood (HDL) method.(9) Similar principle as in estimating heritability, the genetic correlation between two traits is estimated by contrasting the covariance matrix of z-scores 1 (trait 1)-z-scores 2 (trait 2) and the LD scores matrix.(10) HDL exploits all elements of the z-scores covariance matrix instead of just the diagonal elements in LDSC, and thus yields more precise estimates of genetic correlations compared to LDSC.(9) We estimated genetic correlations within subtype comparisons, using the LD reference computed from 335,265 Genomic British individuals in the UKB.

For the primary analysis, we estimated genetic correlation for each pair of subgroups within a comparison group. GWAS summary statistics data were processed into the right format with z-scores by HDL.data.wrangling.R function in HDL program (https://github.com/zhenin/HDL/wiki/Format-of-summary-statistics). LD reference panel used is the eigenvalues and eigenvectors of LD matrices for the European-ancestry population. The matrices were computed from 335,265 Genomic British individuals in UK Biobank (https://github.com/zhenin/HDL/wiki/Reference-panels). Details about the HDL program could be found at <https://github.com/zhenin/HDL/wiki>.

### **Sensitivity analyses**

It has been argued that results relying on minimal phenotyping (*i.e.*, the definitions of MD are not strictly based on structured clinical interviews, but instead rely on a few self-reported answers) may bias views of genetic architecture of MD.(5) To examine whether our broad MD definition may bias the results, we further restricted the analyses to the CIDI-based definition—previously suggested as the closest to the gold standard for diagnosing MD in the UKB(5, 11)—and estimated SNP heritability and genetic correlations for all subtypes except impairment because moderate to severe impairment is part of the CIDI-based MD criteria.

Cases of subtypes were defined using the same criteria as primary analyses, then we only included people who also met criteria for CIDI-based MD *(Supplementary table S2.3).*  Control group was the same as in the primary GWAS analyses. After estimating SNP-heritability on the observed scale using LDSC, we converted to the liability scale using the same population case and control prevalence as in primary analyses *(Supplementary table S2.5).* Estimates of *h2SNP* and*rg* are is *Supplementary table S2.7*.

1. SUPPLEMENTARY TABLES

## **Table S2.1 Method to derive of MD cases, control and exclusion criteria in UKB**

|  |  |  |  |
| --- | --- | --- | --- |
| **Measure** | **Description** | **Criteria** | **Derive method** |
| CIDI-SF based MD | Lifetime or current MDD according to DSM-V criteria | **Life-time CIDI MD**5/8 criteria A1-A9 (lack A5) with at least one criteria A1 or A2 plus criteria BCDE as below:A1 (UKB 20446)A2 (UKB 20441)A3 (UKB 20536)A4 (UKB 20532)A6 (UKB 20449)A7 (UKB 20450)A8 (UKB 20435)A9 (UKB 20437)B - Impact on normal roles during worst period of depression (UKB 20440)C - Not substance abuse (UKB 41202 + 41202)D- Not SCZ or psychotic (UKB 41202 + 41202E - Not Maniac (UKB 41202 + 41202)**Current CIDI MD**- 5/9 criteria with at least one criteria A1 or A2 (each satisfied A criteria scores 1)A1 (UKB 20510) = 4A2 (UKB 20514) = 4A3 (UKB 20511) = 4A4 (UKB 20517) = 4A5 (UKB 20518) = 4A6 (UKB 20519) = 4A7 (UKB 20507) = 4A8 (UKB 20508) = 4A9 (UKB 20513) = 4B - Plus Impact on normal roles during worst period of depression (UKB 20440)C - Plus Not substance abuse (UKB 41202 + 41204)D - Plus Not SCZ or psychotic (UKB 41202 + 41204)E - Plus Not Maniac (UKB 41202 + 41204) | **Life-time CIDI MD**UKB20446 = 1 or UKB20441 = 1andsum UKB(20446, 20441, 20536, 20532, 20449, 20450, 20435, 20437) >=5and UKB20440 = 3and UKB41202 != (F10-F19, F20-F29, F30)andUKB41204 != (F10-F19, F20-F29, F30)**Current CIDI MD**UKB20510 = 1 or UKB20514 = 1andsum UKB(20510, 20514, 20511, 20517, 20518, 20519, 20507, 20508, 20513) >=5and UKB20440 = 3and UKB41202 != (F10-F19, F20-F29, F30)andUKB41204 != (F10-F19, F20-F29, F30)**CIDI-based MD**Life-time CIDI MD = 1 or Current CIDI MDD = 1 |
| ICD-coded MD | Clinician diagnosis of MDD  | Any primary or secondary diagnosis of a depressive mood disorder from linked hospital admission records (UKB 41202 + 41204)  | UKB41202 = F32/F33/F34/F38/F39or UKB41204 = F32/F33/F34/F38/F39  |
| Probable MD |  | Depressed/down for a whole week (UKB: 4598);AndAt least 2 weeks duration (UKB: 4609);AndEver seen a GP or psychiatrist for nerves, anxiety or depression” (UKB 2090 + 2010)Or Ever anhedonia for a whole week (UKB 4631); plus At least 2 weeks duration (UKB 5375); And Ever seen a GP or psychiatrist for nerves, anxiety, or depression (UKB 2090 + 2010) | UKB20126 = 3/4/5  |
| Self-reported MD | Self-reported ever had MDD diagnosis or non-cancer diseases including MD | Self-reported depression (UKB 20002)orSelf-reported Mental health problems ever diagnosed by a professional (UKB 20544) | UKB20002 = 1286orUKB20544 = 11 |
| MD cardinal symptoms | Ever had indication of depression | Ever had prolonged loss of interest in normal activities (UKB 20441); or prolonged feelings of sadness or depression (UKB 20446) | UKB20441 = 1 orUKB20446 = 1 |
| MD broad phenotype | The MD broad definition to define cases in the study | Meet at least 1 measure 1-5 | CIDI-SF based MD = 1orICD-coded MD = 1orProbable MD = 1orSelf-reported MD = 1orMD cardinal symptoms = 1 |
| Help-seeking MD | Self-reported help-seeking behavior for mental health difficulties | Ever seen a general practitioner (GP) for nerves, anxiety, tension or depression (UKB 2090)or Ever seen a psychiatrist for nerves, anxiety, tension or depression (UKB 2010) | UKB2090 = 1 orUKB2100 = 1 |
| Antidepressant use | Self-reported use of antidepressants as regular medication and health supplements | Reported use of any antidepressant (UKB 20003) | UKB20003 = any code in the list of antidepressants |
| Control MD | Controls of MD population | Not meeting any of 7 MD definitions 1-7 as above | CIDI-SF based MD != 1andICD-coded MD != 1andProbable MD != 1andSelf-reported MD != 1andMD cardinal symptoms != 1andHelp-seeking MD !=1andAntidepressant use != 1 |
| Control postpartum MD | Controls of PPD population | Women (UKB 31)and Have given >= 1 live birth (UKB 2734) and Not meeting any of 7 MD definitions 1-7 as above | Control MD = 1andUKB31 = 0andUKB2734 > 0 |
| Control comorbid anxiety MD | Control for cases in the comorbid anxiety subtype | Not meeting any of 7 MD definitions 1-7 as aboveand Not having anxiety disorder F40/F41 (UKB 41202, 41204) | Control MD = 1andUKB41202 != (F40, F41)andUKB41204 != (F40, F41) |
| Exclusion criteria | Criteria to excluded cases and controls | Do not have diagnosis of SCZ/psychosis (F20-F29), BP (F31) and Manias (F30) (UKB 41202 + 41204)and Do not used antipsychotics or lithium (UKB 20003) | UKB41202 != (F10-F19, F20-F29, F30)andUKB41204 != (F10-F19, F20-F29, F30)andUKB20003 != any code in the list of antipsychotics and lithium |
| *\*Note: != means NOT EQUAL; coding 0 = No; 1 = Yes for binary variables; otherwise, check https://biobank.ctsu.ox.ac.uk/crystal/index.cgi* |

## **Table S2.2 MD definitions and derived subtypes**

|  |  |  |  |
| --- | --- | --- | --- |
| **Source** | **MD definitions** | **N (%**\***)** | **Derived subtype** |
| MHQ online questionnaire | CIDI-SF based MD | 17,121 (3.76%) | * Recurrence
 |
| Hospital admission records | ICD-coded MD | 12,135 (2.66%) | * Severity
* Comorbid anxiety
* Postpartum
 |
| Touchscreen questionnaire (mental health) | Probable MD | 28,628 (6.28%) | * Recurrence
* Severity
 |
| Nurse interview | Self-reported MD | 50,857 (11.15%) | * Comorbid anxiety
* Postpartum
 |
| MHQ online questionnaire | MD cardinal symptoms | 83,774 (18.37%) | * Age at onset
* Suicidal thought
* Atypical features
* Impairment
 |
| *CIDI-SF = Composite International Diagnostic Interview Short Form | MHQ = Mental health questionnaire**\*Proportion of total 459,590 included sample* |

## **Table S2.3 Method to derive MD subtypes in UKB data**

|  |  |  |  |
| --- | --- | --- | --- |
| **Subtypes** | **Description** | **Subtype within MD broad phenotypea** | **Subtype within CIDI-SF based MDb** |
| **Vegetative symptoms** |
| Atypical features | MD with atypical features Hypersomnia (UKB20534) and weight gain (UKB20536) | MD broad phenotype = 1 and(UKB20534 = 1 and UKB20536 = 1) | CIDI-SF-based MD = 1 and(UKB20534 = 1 and UKB20536 = 1) |
| Non-atypical | MD without atypical features. i.e., did not have hypersomnia and weight gain at the same time | MD broad phenotype = 1 and(UKB20534 = 0 and/or UKB20536 = 0) | CIDI-SF-based MD = 1 and(UKB20534 = 0 and/or UKB20536 = 0) |
| **Severity** |
| Severe | Severe episode MD ascertained by self-report and ICD diagnostic codes (UKB20126, UKB41202, UKB41202) | MD broad phenotype = 1 and(UKB20126 = 3 or UKB41202 = F322/F323/ F332/F333 or UKB41204 = F322/F323/ F332/F333) | CIDI-SF-based MD = 1 and(UKB20126 = 3 or UKB41202 = F322/F323/ F332/F333 or UKB41204 = F322/F323/ F332/F333) |
| Mild/moderate | Mild and moderate MD ascertained by self-report and ICD diagnostic codes (UKB20126, UKB41202, UKB41202) | MD broad phenotype = 1 and(UKB20126 = 4 or UKB41202 = F320/F321/ F330/F331 or UKB41204 = F320/F321/F330/F331)and not included in severe subtype | CIDI-SF-based MD = 1and(UKB20126 = 4 or UKB41202 = F320/F321/ F330/F331 or UKB41204 = F320/F321/F330/F331)and not included in severe CIDI-SF -based subtype |
| **Comorbid anxiety** |
| Comorbid anxiety | MD WITH comorbid anxiety, panic attacks, social anxiety/phobia (UKB 20544, UKB41202, UKB41204) | MD broad phenotype = 1 and(UKB20544 = 1/6/15 or UKB41202 = F40, F41 or UKB41204 = F40, F41) | CIDI-SF-based MD = 1 and(UKB20544 = 1/6/15 or UKB41202 = F40, F41 or UKB41204 = F40, F41) |
| Non-comorbid anxiety | MD WITHOUT comorbid anxiety, panic attacks, social anxiety/phobia (UKB 20544, UKB41202, UKB41204) | MD broad phenotype = 1 and(UKB20544 != 1/6/15 and UKB41202 != F40, F41 and UKB41204 != F40, F41) | CIDI-SF-based MDD = 1 and(UKB20544 != 1/6/15 and UKB41202 != F40, F41 and UKB41204 != F40, F41) |
| **Age at onset** |
| Early onset | Age at first episode of depression ≤ 30 (UKB20433) | MD broad phenotype = 1 andUKB20433 = [2,30]  | CIDI-SF-based MD = 1 andUKB20433 = [2,30]  |
| Late onset | Age at first episode of depression ≥ 44 (UKB20433) | MD broad phenotype = 1 andUKB20433 = (43,78]  | CIDI-SF-based MD = 1 andUKB20433 = (43,78]  |
| **Recurrence** |
| Recurrent | MD with recurrent episodes (UKB20126, UKB41202, UKB41204) | MD broad phenotype = 1 and(UKB20126 = 3/4 or (CIDI-SF-based MDD = 1 and UKB20442 ≥ 2) or UKB41202 = F33 or UKB41204 = F33) | CIDI-SF-based MD = 1 and(UKB20126 = 3/4 or (CIDI-SF-based MDD = 1 and UKB20442 ≥ 2) or UKB41202 = F33 or UKB41204 = F33) |
| Single | MD with single episode (UKB20126, UKB41202, UKB41204) | MD broad phenotype = 1 and(UKB20126 = 5 or (CIDI-SF-based MDD = 1 and UKB20442 < 2) or UKB41202 = F32 or UKB41204 = F32)andNot in recurrent subtype | CIDI-SF-based MD = 1 and(UKB20126 = 5 or (CIDI-SF-based MDD = 1 and UKB20442 < 2) or UKB41202 = F32 or UKB41204 = F32)andNot in CIDI-SF-based recurrent MD subtype |
| **Suicidality** |
| Yes | Having suicidal thought during the worst period of or recent thoughts of suicide or self-harm more than half of days or nearly every day (UKB20437, UKB20513) | MD broad phenotype = 1 and(UKB20437 = 1 or 20513 = 3/4) | CIDI-SF-based MD = 1 and(UKB20437 = 1 or 20513 = 3/4) |
| No | Not having suicidal thought or recent thoughts of suicide or self-harm (UKB20437, UKB20513) | MD broad phenotype = 1 and(UKB20437 = 0 and UKB20513 = 1) | CIDI-SF-based MD = 1 and(UKB20437 = 0 and UKB20513 = 1) |
| **Impairment** |
| Mild | Impact on normal roles during worst period of depression is not at all or a little (UKB20440) | MD broad phenotype = 1 andUKB20440 = 0/1 | N/A |
| Moderate | Impact on normal roles during worst period of depression somewhat (UKB20440) | MD broad phenotype = 1 andUKB20440 = 2 | N/A |
| Severe | Impact on normal roles during worst period of depression a lot (UKB20440) | MD broad phenotype = 1 andUKB20440 = 3 | N/A |
| **Postpartum MD** |
| MD relating to child birth | MD relating to child birth ascertained by self-report (UKB 20002, UKB 20445) and ICD code (UKB: 41202 and 41204) | MD broad phenotype = 1 and(UKB20002 = 1531 or UKB20445 = 1 or UKB41202 = F53 or UKB41204 = F53) | CIDI-SF-based MD = 1and(UKB20002 = 1531 or UKB20445 = 1 or UKB41202 = F53 or UKB41204 = F53) |
| *aSubtypes in primary analyse | bSubtypes in sensitivity analyses* |

## **Table S2.4 Medication list**

|  |  |  |  |
| --- | --- | --- | --- |
| **ID†** | **Medication name** | **ID†** | **Medication name** |
| **Antidepressant** |
| 1140879616 | amitriptyline | 1141151978 | reboxetine |
| 1140921600 | citalopram | 1141152736 | zispin |
| 1140879540 | fluoxetine | 1140867640 | doxepin |
| 1140867878 | sertraline | 1140867920 | moclobemide |
| 1140916282 | venlafaxine | 1140867850 | phenelzine |
| 1140909806 | dosulepin | 1140879544 | fluvoxamine |
| 1140867888 | paroxetine | 1141200570 | yentreve |
| 1141152732 | mirtazapine | 1140867934 | triptafen |
| 1141180212 | escitalopram | 1140867758 | surmontil |
| 1140879634 | trazodone | 1140867914 | tranylcypromine |
| 1140867876 | prozac | 1140867820 | allegron |
| 1140882236 | seroxat | 1141151982 | edronax |
| 1141190158 | cipralex | 1140882244 | molipaxin |
| 1141200564 | duloxetine | 1140879556 | mianserin |
| 1140867726 | lofepramine | 1140867852 | nardil |
| 1140879620 | clomipramine | 1140867860 | faverin |
| 1140867818 | nortriptyline | 1140917460 | nefazodone |
| 1140879630 | imipramine | 1140867938 | Amitriptyline + chlordiazepoxide |
| 1140879628 | dothiepin | 1140867856 | isocarboxazid |
| 1141151946 | cipramil | 1140867922 | manerix |
| 1140867948 | amitriptyline | 1140910820 | maoi |
| 1140867624 | prothiaden | 1140882312 | sinequan |
| 1140867756 | trimipramine | 1140867944 | Tranylcypromine + trifluoperazine |
| 1140867884 | lustral | 1140867784 | ludiomil |
| 1141201834 | cymbalta | 1140867812 | norval |
| 1140867690 | anafranil | 1140867668 | tryptizol |
| **Antipsychotic** |
| 1140928916 | olanzapine | 1141202024 | abilify |
| 1141152848 | quetiapine | 1140882098 | fluphenazine |
| 1140867444 | risperidone | 1140867184 | haldol |
| 1140879658 | chlorpromazine | 1140867092 | serenace |
| 1140868120 | trifluoperazine | 1140882320 | clozaril |
| 1141153490 | amisulpride | 1140910358 | cpz |
| 1140867304 | sulpiride | 1140867208 | perphenazine |
| 1141152860 | seroquel | 1140909802 | levomepromazine |
| 1140867168 | haloperidol | 1140867134 | pericyazine |
| 1141195974 | aripiprazole | 1140867306 | dolmatil |
| 1140867244 | stelazine | 1140867210 | fentazin |
| 1140867152 | depixol | 1140867398 | fluphenazine |
| 1140909800 | flupentixol | 1140867078 | benperidol |
| 1140867420 | clozapine | 1140867218 | pimozide |
| 1140879746 | promazine | 1141201792 | zaponex |
| 1141177762 | risperdal | 1141200458 | denzapine |
| 1140867456 | modecate | 1140867136 | neulactil |
| 1140867952 | fluanxol | 1140879750 | thioridazine |
| 1140867150 | flupenthixol | 1140867180 | dozic |
| 1141167976 | zyprexa | 1140867546 | fluspirilene |
| 1140882100 | zuclopenthixol | 1140928260 | panadeine |
| 1140867342 | clopixol | 1140927956 | sertindole |
| 1140863416 | largactil |  |  |
| **Lithium** |
| 1140867490 | lithium product | 1140867504 | priadel 200mg m/r tablet |
| 1140867494 | camcolit 250 tablet | 1140867518 | litarex 564mg m/r tablet |
| 1140867498 | liskonum 450mg m/r tablet | 1140867520 | li-liquid 5.4mmol/5ml oral solution |
| 1140867500 | phasal 300mg m/r tablet |  |  |
| *This list is from Davis et al., 2019 (PMC6877131)(12) | †ID in UKB data (field 20003)* |

## **Table S2.5 Prevalence of subtypes to convert *h2g*from observed to liability scale**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Phenotype** | ***h2g* observed scale** | **SE observed scale** | **N case** | **N control** | **Sample case prevalencea** | **Population case prevalenceb** | **Population control prevalencec** | **Subtype proportion in literature** | **Source for subtype proportion** |
| Atypical features | 0.0086 | 0.0019 | 2904 | 250229 | 0.0115 | 0.0450 | 0.85 | 0.30 | PMID: 29033570 |
| Non-atypical | 0.0400 | 0.0024 | 46900 | 250229 | 0.1578 | 0.1050 | 0.85 | 0.70 |
| Severe | 0.0143 | 0.0022 | 7923 | 250229 | 0.0307 | 0.0750 | 0.85 | 0.50 | PMID: 29450462 |
| Mild/Moderate | 0.0159 | 0.0018 | 11300 | 250229 | 0.0432 | 0.0750 | 0.85 | 0.50 |
| Co. Anxiety | 0.0416 | 0.0023 | 24543 | 249062 | 0.0897 | 0.0825 | 0.85 | 0.55 | PMID: 11098417 |
| Non-co. anxiety | 0.0268 | 0.0022 | 16480 | 249062 | 0.0621 | 0.0675 | 0.85 | 0.45 |
| Early onset | 0.0489 | 0.0027 | 29292 | 250229 | 0.1048 | 0.0563 | 0.85 | 0.375 | 3 first octiles |
| Late onset | 0.0153 | 0.0019 | 27796 | 250229 | 0.1000 | 0.0563 | 0.85 | 0.375 | 3 last octiles |
| Recurrent | 0.0410 | 0.0025 | 30219 | 250229 | 0.1078 | 0.0525 | 0.85 | 0.35 | PMID: 20003092 |
| Single | 0.0222 | 0.0021 | 20973 | 250229 | 0.0773 | 0.0975 | 0.85 | 0.65 |
| Suicidal | 0.0425 | 0.0025 | 40976 | 250229 | 0.1407 | 0.0900 | 0.85 | 0.60 | PMID: 14628986 |
| Non-suicidal | 0.0359 | 0.0023 | 37140 | 250229 | 0.1292 | 0.0600 | 0.85 | 0.40 |
| Mild impair | 0.0222 | 0.0019 | 28721 | 250229 | 0.1030 | 0.0300 | 0.85 | 0.20 | PMID: 15930066 |
| Moderate impair | 0.0338 | 0.0025 | 28991 | 250229 | 0.1038 | 0.0300 | 0.85 | 0.20 |
| Severe impair | 0.0382 | 0.0025 | 25825 | 250229 | 0.0936 | 0.0900 | 0.85 | 0.60 |
| Postpartum | 0.0250 | 0.0053 | 6333 | 95736 | 0.0620 | 0.10 | 0.90 | 0.10 | PMID: 16260528 |
| CIDI-based MD | 0.0315 | 0.0024 | 17121 | 250229 | 0.0640 | 0.15 | 0.85 |  |   |
| ICD-coded MD | 0.0350 | 0.0025 | 12135 | 250229 | 0.0463 | 0.15 | 0.85 |  |   |
| Probable MD | 0.0299 | 0.0023 | 28628 | 250229 | 0.1027 | 0.15 | 0.85 |  |   |
| Self-reported MD | 0.0628 | 0.0096 | 50857 | 250229 | 0.1689 | 0.15 | 0.85 |  |   |
| Cardinal MD | 0.0579 | 0.0025 | 83774 | 250229 | 0.2508 | 0.15 | 0.85 |  |   |
| Broad MD | 0.0547 | 0.0024 | 124121 | 250229 | 0.3316 | 0.15 | 0.85 |  |   |
| *aSample case prevalence = Ncase/(Ncase + Ncontrol)bPopulation case prevalence = 0.15\*case proportion (except PPD)cPopulation control prevalence = 85% (except PPD)For MD phenotypes, population case prevalence = estimated lifetime prevalence of MD 15%, and population control prevalence = 85%* |

## **Table S2.6 Significant loci in MD subtypes and broad MD phenotype GWAS**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **CHR** | **Region** | **rsID** | **A1/A2** | **AF1** | **Beta** | **SE** | **P** | **Mapped Gene(s)** | **Significant in previous large GWAS†**  | **Significant in broad MD GWAS** | **P-values in GWAS of other subtype in comparison** |
| **Non-atypical features** | **MD with atypical features** |
| 1 | 72511514-72838406 | rs66495454 | G/GTCCT | 0.62 | -0.006801 | 0.0009649 | 1.82e-12 | NEGR1 | PGC+ UKB, Top10K | Yes | 2.51e-03 |
| 6 | 27309779-29548089 | rs9393925 | T/C | 0.14 | -0.007882 | 0.0013368 | 3.71e-09 | >10 genes | PGC+ UKB, Top10K | Yes | 1.18e-01 |
| 12 | 113349833-113349833 | rs55676265 | A/G | 0.79 | -0.006325 | 0.001146 | 3.40e-08 | OAS1 |  | No | 7.98e-01 |
| 13 | 53608084-53842904 | rs2806950 | G/A | 0.38 | 0.0058023 | 0.0009647 | 1.80e-09 | OLFM4 | Top10K | Yes | 6.54e-03 |
| 17 | 56424710-56451552 | rs56058331 | G/A | 0.58 | -0.005225 | 0.0009442 | 3.12e-08 | SUPT4H1, RNF43 | \* | No | 8.17e-01 |
| 19 | 4944555-5022857 | rs59562763 | G/GC | 0.65 | -0.005594 | 0.0009773 | 1.04e-08 | KDM4B | \* | Yes | 5.77e-02 |
| **Anxiety** | **Non-anxiety** |
| 1 | 72544704-72748567 | rs66495454 | G/GTCCT | 0.62 | -0.004494 | 0.0007939 | 1.51e-08 | NEGR1 | PGC+ UKB, Top10K | Yes | 5.36e-04 |
| 7 | 12233848-12286050 | rs3807866 | G/A | 0.59 | -0.004777 | 0.0007765 | 7.67e-10 | TMEM106B | PGC+ UKB, Top10K | Yes | 4.03e-03 |
| 9 | 11275587-11771159 | rs958538 | T/C | 0.75 | 0.0052401 | 0.0008888 | 3.72e-09 |  | PGC+ UKB, Top10K | No | 8.49e-01 |
| 14 | 103833065-104000802 | 14:103964545\_TA\_T | TA/T | 0.30 | -0.00468 | 0.0008506 | 3.75e-08 | MARK3, CKB, TRMT61A | PGC+ UKB, Top10K | Yes | 1.73e-03 |
| **Early onset** | **Late onset** |
| 1 | 72511514-72838406 | rs7542974 | G/A | 0.75 | -0.006992 | 0.0009356 | 7.79e-14 | NEGR1 | PGC+ UKB, Top10K | Yes | 6.72e-02 |
| 2 | 34996836-35088235 | 2:35034680\_CGA\_C | CGA/C | 0.50 | 0.0045422 | 0.0008183 | 2.84e-08 |  | \* | No | 4.94e-02 |
| 3 | 85517112-86192846 | rs10865612 | T/C | 0.65 | -0.006005 | 0.0008439 | 1.11e-12 | CADM2 | \* | No | 9.21e-01 |
| 6 | 27374680-27486633 | rs6914846 | A/G | 0.40 | -0.004597 | 0.0008405 | 4.50e-08 | ZNF391, ZNF184 | PGC+ UKB, Top10K | Yes | 8.07e-05 |
| 6 | 29530868-29530868 | rs362529 | C/T | 0.85 | -0.006333 | 0.0011256 | 1.84e-08 | UBD, GABBR1 | \* | No | 2.41e-01 |
| 7 | 24548616-24801999 | rs2711093 | C/T | 0.70 | -0.005087 | 0.0008878 | 1.00e-08 | MPP6, DFNA5 |  | Yes | 2.67e-02 |
| 9 | 16713666-16784682 | rs35261422 | A/AT | 0.78 | 0.0055289 | 0.0009801 | 1.69e-08 | BNC2 | \* | No | 9.07e-01 |
| 10 | 126711107-126738471 | rs34260682 | G/A | 0.91 | 0.0080136 | 0.0014651 | 4.51e-08 | CTBP2 |  | No | 6.83e-02 |
| 13 | 53608084-53675539 | rs3803259 | G/C | 0.48 | 0.004627 | 0.0008207 | 1.72e-08 | OLFM4 | Top10K | Yes | 2.25e-04 |
| 14 | 60179792-60663420 | rs216519 | C/A | 0.62 | -0.004633 | 0.0008292 | 2.31e-08 | RTN1, LRRC9, PCNXL4, DHRS7 |  | No | 1.69e-01 |
| 16 | 13665985-13805809 | rs56225373 | T/G | 0.86 | -0.007167 | 0.0011813 | 1.31e-09 |  | PGC+ UKB, Top10K | No | 4.79e-01 |
| 19 | 18182266-18279816 | rs11667720 | G/C | 0.57 | -0.005102 | 0.0008443 | 1.52e-09 | IL12RB1, MAST3, PIK3R2, IFI30 | \* | No | 6.28e-02 |
| 20 | 59827231-59827231 | rs143502921 | G/C | 0.82 | -0.007866 | 0.0011784 | 2.48e-11 | CDH4 | \* | Yes | 8.19e-02 |
| **Recurrent** | **Single** |
| 2 | 15311954-15468791 | rs6431690 | T/C | 0.55 | 0.0049644 | 0.0008249 | 1.76e-09 | NBAS |  | No | 3.22e-04 |
| 2 | 152886708-153120132 | rs62175074 | T/C | 0.79 | -0.005797 | 0.0010494 | 3.31e-08 | CACNB4 | \* | No | 2.41e-02 |
| 2 | 212702426-212778384 | rs74338595 | T/C | 0.71 | 0.0050054 | 0.000902 | 2.87e-08 | ERBB4 |  | No | 8.71e-01 |
| 5 | 164467717-164588817 | rs543533963 | C/T | 0.45 | -0.004596 | 0.0008369 | 3.98e-08 |  | PGC+ UKB, Top10K | No | 2.81e-01 |
| 6 | 26309908-29607101 | rs1233393 | C/G | 0.87 | 0.0080081 | 0.0012237 | 5.98e-11 | >10 genes | PGC+ UKB, Top10K | Yes | 2.45e-03 |
| 11 | 88472034-88978545 | rs1942496 | G/A | 0.51 | 0.0048128 | 0.0008266 | 5.81e-09 | GRM5, TYR | PGC+ UKB, Top10K | Yes | 3.86e-03 |
| 19 | 31891006-31927547 | rs2111530 | A/G | 0.61 | -0.004796 | 0.0008415 | 1.20e-08 |  |  | Yes | 4.59e-01 |
| **Suicide** | **Non-suicide** |
| 1 | 109873290-110040460 | rs11590351 | T/C | 0.75 | -0.005993 | 0.0010409 | 8.54e-09 | SORT1, PSMA5, SYPL2, ATXN7L2, CYB561D1, AMIGO1 |  | No | 4.77e-03 |
| 4 | 2412967-2439670 | rs113065538 | C/A | 0.35 | 0.0052159 | 0.0009451 | 3.41e-08 | ZFYVE28 |  | No | 2.33e-02 |
| 11 | 90528418-90646073 | rs10830592 | A/G | 0.32 | -0.005374 | 0.0009633 | 2.43e-08 |  |  | No | 6.31e-02 |
| **Non-suicide** | **Suicide** |
| 1 | 72544704-72838406 | rs66495454 | G/GTCCT | 0.62 | -0.005658 | 0.0009131 | 5.79e-10 | NEGR1 | PGC+ UKB, Top10K | Yes | 8.62e-08 |
| 1 | 239697408-239760514 | rs12118109 | G/A | 0.96 | -0.012083 | 0.0022117 | 4.68e-08 | CHRM3 |  | No | 8.03e-01 |
| 6 | 27374680-27486633 | rs6914846 | A/G | 0.40 | -0.005081 | 0.0009166 | 2.96e-08 | ZNF391, ZNF184 | PGC+ UKB, Top10K | Yes | 2.18e-05 |
| 10 | 76463067-76506933 | rs9733673 | G/T | 0.85 | -0.007468 | 0.0012748 | 4.68e-09 | ADK |  | No | 9.58e-01 |
| 15 | 83170194-83337059 | rs35385880 | C/CT | 0.35 | -0.005242 | 0.0009213 | 1.27e-08 | RPS17L, RP11-152F13.10, RP11-379H8.1, CPEB1, AP3B2 | \* | No | 1.34e-03 |
| **Moderate impairment** | **Mild** | **Severe** |
| 1 | 72748567-72838406 | rs66495454 | G/GTCCT | 0.62 | -0.005477 | 0.0008398 | 6.95e-11 | NEGR1 | PGC+ UKB, Top10K | Yes | 4.23e-03 | 6.81e-09 |
| 1 | 243197475-243500994 | rs4658548 | C/T | 0.63 | 0.0047129 | 0.0008374 | 1.82e-08 | CEP170, AC092782.1, SDCCAG8 |  | No | 1.25e-02 | 5.54e-02 |
| 16 | 10472145-10596428 | rs141035531 | C/G | 0.98 | -0.01648 | 0.0028972 | 1.28e-08 | ATF7IP2 | \* | No | 2.25e-03 | 2.45e-01 |
| **Severe impairment** | **Mild** | **Moderate** |
| 1 | 72511514-72748567 | rs7542974 | G/A | 0.75 | -0.005233 | 0.0009012 | 6.37e-09 | NEGR1 | PGC+ UKB, Top10K | Yes | 1.21e-03 | 2.18e-06 |
| 5 | 164334125-164678946 | rs10476484 | A/G | 0.73 | -0.005255 | 0.0008776 | 2.13e-09 |  | PGC+ UKB, Top10K | No | 4.73e-01 | 1.73e-01 |
| 6 | 27321848-27476592 | rs6456788 | C/T | 0.35 | -0.00448 | 0.000811 | 3.32e-08 | ZNF391, ZNF184 | PGC+ UKB, Top10K | Yes | 1.82e-03 | 3.48e-04 |
| 6 | 27868792-29548089 | rs9393925 | T/C | 0.14 | -0.006249 | 0.0011136 | 2.01e-08 | >10 genes | PGC+ UKB, Top10K | Yes | 4.04e-03 | 1.53e-02 |
| 13 | 53608084-53675691 | rs12552 | A/G | 0.44 | 0.0049643 | 0.000785 | 2.55e-10 |  | Top10K | Yes | 1.21e-01 | 2.16e-07 |
| **PPD** |  |
| 2 | 189234143-189682431 | rs11683671 | C/A | 0.93 | -0.011889 | 0.0021379 | 2.68e-08 | GULP1 |  | No | - |
| **MD broad phenotype** |  |
| 1 | 37663818-37680479 | rs215849 | C/G | 0.76 | -0.007455 | 0.0012812 | 5.95e-09 |  | \* | - | - |
| 1 | 71815804-73699761 | rs66495454 | G/GTCCT | 0.62 | -0.009214 | 0.0011084 | 9.32e-17 | NEGR1 | PGC+ UKB, Top10K | - | - |
| 1 | 197342380-197813558 | rs12123169 | T/A | 0.79 | 0.0078402 | 0.0013154 | 2.51e-09 | CRB1，DENND1B | PGC+ UKB, Top10K | - | - |
| 2 | 23178683-23183651 | rs6744716 | T/A | 0.69 | -0.006393 | 0.0011539 | 3.02e-08 |  |  | - | - |
| 2 | 34996836-35092802 | rs2083210 | G/T | 0.56 | 0.0060188 | 0.0010815 | 2.62e-08 |  |  | - | - |
| 2 | 155654466-156116188 | rs1037094 | C/A | 0.79 | 0.0073764 | 0.0013236 | 2.50e-08 | KCNJ3 |  | - | - |
| 5 | 87981030-88175251 | rs28712135 | T/A | 0.53 | 0.0062953 | 0.001084 | 6.33e-09 | MEF2C | Top10K\* | - | - |
| 5 | 103671867-104082179 | rs30266 | G/A | 0.67 | -0.006767 | 0.0011399 | 2.92e-09 |  | PGC+ UKB, Top10K | - | - |
| 6 | 25417423-29607101 | rs10807023 | G/A | 0.38 | -0.008023 | 0.0010984 | 2.79e-13 | >10 genes | PGC+ UKB, Top10K | - | - |
| 7 | 12233848-12286050 | rs3807865 | G/A | 0.59 | -0.006048 | 0.0010847 | 2.46e-08 | TMEM106B | PGC+ UKB, Top10K | - | - |
| 7 | 24590979-24779987 | rs2529047 | G/A | 0.70 | -0.006832 | 0.0011757 | 6.20e-09 | MPP6, DFNA5 |  | - | - |
| 11 | 31808280-31856654 | rs7942007 | A/G | 0.81 | -0.007607 | 0.0013786 | 3.43e-08 | ELP4, PAX6, RCN1 | Top10K | - | - |
| 11 | 88470041-89026407 | 11:88769807 | GGCAAGACTATTAATCAGTATTTGTACTCAAATTTGCCCCAAAGTCCCTCAACTA/G | 0.42 | 0.00691 | 0.0010923 | 2.52e-10 | GRM5, TYR | PGC+ UKB, Top10K | - | - |
| 13 | 53608084-53675539 | rs3803259 | G/C | 0.48 | 0.0071274 | 0.0010885 | 5.84e-11 | OLFM4 | PGC+ UKB, Top10K | - | - |
| 13 | 69779070-70024608 | rs7989827 | T/G | 0.52 | 0.0059779 | 0.0010722 | 2.47e-08 |  |  | - | - |
| 14 | 60155307-60247284 | 14:60156702\_CT\_C | CT/C | 0.35 | 0.0064217 | 0.0011488 | 2.27e-08 | RTN1 | \* | - | - |
| 14 | 103833065-104093521 | rs2071408 | G/A | 0.63 | 0.007253 | 0.0011139 | 7.46e-11 | MARK3, CKB, TRMT61A, BAG5,KLC1, RP11-73M18.2, APOPT1 | PGC+ UKB, Top10K | - | - |
| 15 | 74010301-74062710 | rs4327001 | G/A | 0.59 | -0.006012 | 0.0010876 | 3.24e-08 | CD276, C15orf59 |  | - | - |
| 18 | 50364022-51059160 | rs112633410 | G/A | 0.57 | -0.006451 | 0.0010823 | 2.51e-09 | DCC | PGC+ UKB, Top10K | - | - |
| 19 | 4944555-5022857 | rs58324296 | A/C | 0.65 | -0.006414 | 0.0011247 | 1.18e-08 | KDM4B |  | - | - |
| 19 | 31891006-31927547 | rs2111530 | A/G | 0.60 | -0.006013 | 0.0010973 | 4.25e-08 |  |  | - | - |
| 20 | 59827231-59827231 | rs143502921 | G/C | 0.82 | -0.010453 | 0.0015601 | 2.08e-11 | CDH4 | \* | - | - |

\*Some variants in those loci were not analyzed in PGC+UKB GWAS, which might be excluded in quality control or not examined.

**†**Top10K: Data contains genome-wide summary statistics of the most informative 10,000 variants from a meta-analysis of the 33 cohorts of the Psychiatric Genomics Consortium, the broad depression phenotype in the full release of the UK Biobank and 23andMe data

PGC+UKB: Data contains genome-wide summary statistics from a meta-analysis of the 33 cohorts of the Psychiatric Genomics Consortium (excluding UK Biobank and 23andMe data) and the broad depression phenotype in the full release of the UK Biobank

Citation: Howard et al (2019) [dataset] (13).

## **Table S2.7 SNP-heritability and genetic correlation for subtypes within CIDI-SF MD cases**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | *h2SNP* **observed scale** | **Se observed scale** | **N case** | **N control** | **Sample case prevalence** | *h2SNP* **liability scale** | **Se liability scale** | **rg** | **Se rg** | **95% CI rg** |
| Atypical features CIDI | 0.0066 | 0.0019 | 1325 | 250229 | 0.0053 | 0.2209 | 0.06359 | 0.5912 | 0.0942 | 0.4066; 0.7758 |
| Non-atypical CIDI | 0.0215 | 0.0022 | 11928 | 250229 | 0.0455 | 0.123 | 0.01259 |  |  |  |
| Severe CIDI | 0.0010 | 0.0022 | 1175 | 250229 | 0.0047 | 0.0457 | 0.10064 | 0.9781 | 0.2724 | 0.4442; 1.5120 |
| Mild/moderate CIDI | 0.0020 | 0.0016 | 1424 | 250229 | 0.0057 | 0.0755 | 0.06041 |  |  |  |
| Co. anxiety CIDI | 0.0217 | 0.0023 | 7303 | 249062 | 0.0285 | 0.1746 | 0.01851 | 0.7739 | 0.0634 | 0.6496; 0.8982 |
| Non-co. Anxiety CIDI | 0.0125 | 0.002 | 5920 | 249062 | 0.0232 | 0.1131 | 0.0181 |  |  |  |
| Early CIDI | 0.0210 | 0.0022 | 6570 | 250229 | 0.0256 | 0.161 | 0.01686 | 0.6021 | 0.084 | 0.4375; 0.7667 |
| Late CICI | 0.0066 | 0.0018 | 5498 | 250229 | 0.0215 | 0.06 | 0.01636 |  |  |  |
| Recurrent CIDI | 0.0265 | 0.0023 | 11094 | 250229 | 0.0425 | 0.1213 | 0.01053 | 0.8402 | 0.0947 | 0.6546; 1.0258 |
| Single CIDI | 0.0091 | 0.0018 | 5602 | 250229 | 0.0219 | 0.102 | 0.02017 |  |  |  |
| Suicide CIDI | 0.0226 | 0.0022 | 10492 | 250229 | 0.0402 | 0.1356 | 0.0132 | 0.7641 | 0.0802 | 0.6069; 0.9213 |
| Non-suicide CIDI | 0.0118 | 0.002 | 5500 | 250229 | 0.0215 | 0.1098 | 0.01862 |  |  |  |
| PPD CIDI | 0.0131 | 0.0046 | 1588 | 95736 | 0.0163 | 0.2149 | 0.07545 |  |  |  |
| N case = number of cases as defined in *Supplementary table S2.3* and was used in GWASN control = number of controls as defined in *Supplementary table S2.1* and was used in GWASSample case prevalence = N case/(N case + N control)*h2SNP* were converted from observed to liability scale using the same population case and control as in *Supplementary table S2.5* |

1. **SUPPLEMENTARY FIGURES**

## **Figure S3.1 Included sample of study**

The dataset from UKB contains 502616 observations. We excluded those who 1) did not have genotype data or unmatched ID in phenotype and genotype datasets, 2) withdraw consent, 3) Low-quality genotype data, and 4) ancestry outliers (whose first two principal components exceeded three standard deviations from the means of 1000 Genome European samples). We retained 459,590 observations.

Then, we defined MD cases and controls as in *Supplementary table S2.1*. We identified 126,506 people who met at least one of the 5 MD definitions, and 250,460 controls.

We applied case and control exclusion criteria as defined in *Supplementary table S2.1, we retained 455,956 observations with 124,121 cases and 250,229 controls.*

Included sample

459,590

Exclude 43,026

UKB cohort

502,616

* No genotype/unmatched ID 14,253
* Withdraw consent 111
* Low-quality genotype 968
* Ancestry outliers 27,694

Controls

250,460

Final control

250,229

Exclude 231

Final cases

124,121

Cases

126,506

Exclude 2385

**Figure S3.1:** Included sample

## **Figure S3.2 SNP- heritability for MD definitions in UKB**



**Figure S3.2** SNP- heritability for MD definitions in UKB

Blue circle shows point estimates for SNP-heritability on liability scale. Estimates on observed scales and populations prevalence to convert to liability scale is in *Supplementary table S2.5*. Error bars show 95% confidence intervals.

# **REFERENCES**

1. Brailean A, Curtis J, Davis K, Dregan A, Hotopf M. Characteristics, comorbidities, and correlates of atypical depression: evidence from the UK Biobank Mental Health Survey. Psychological Medicine. 2020;50(7):1129-38.

2. Smith DJ, Nicholl BI, Cullen B, Martin D, Ul-Haq Z, Evans J, et al. Prevalence and Characteristics of Probable Major Depression and Bipolar Disorder within UK Biobank: Cross-Sectional Study of 172,751 Participants. PLOS ONE. 2013;8(11):e75362.

3. Power RA, Tansey KE, Buttenschøn HN, Cohen-Woods S, Bigdeli T, Hall LS, et al. Genome-wide Association for Major Depression Through Age at Onset Stratification: Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. Biological Psychiatry. 2017;81(4):325-35.

4. Hagenaars SP, Coleman JRI, Choi SW, Gaspar H, Adams MJ, Howard DM, et al. Genetic comorbidity between major depression and cardio-metabolic traits, stratified by age at onset of major depression. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2020;183(6):309-30.

5. Cai N, Revez JA, Adams MJ, Andlauer TFM, Breen G, Byrne EM, et al. Minimal phenotyping yields genome-wide association signals of low specificity for major depression. Nature Genetics. 2020;52(4):437-47.

6. Jiang L, Zheng Z, Qi T, Kemper KE, Wray NR, Visscher PM, et al. A resource-efficient tool for mixed model association analysis of large-scale data. Nature Genetics. 2019;51(12):1749-55.

7. Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nature Genetics. 2015;47(3):291-5.

8. Yap CX, Sidorenko J, Marioni RE, Yengo L, Wray NR, Visscher PM. Misestimation of heritability and prediction accuracy of male-pattern baldness. Nat Commun. 2018;9(1):2537.

9. Ning Z, Pawitan Y, Shen X. High-definition likelihood inference of genetic correlations across human complex traits. Nature Genetics. 2020;52(8):859-64.

10. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh P-R, et al. An atlas of genetic correlations across human diseases and traits. Nature Genetics. 2015;47(11):1236-41.

11. Glanville KP, Coleman JRI, Howard DM, Pain O, Hanscombe KB, Jermy B, et al. Multiple measures of depression to enhance validity of Major Depressive Disorder in the UK Biobank. medRxiv. 2020:2020.09.18.20196451.

12. Davis KAS, Cullen B, Adams M, Brailean A, Breen G, Coleman JRI, et al. Indicators of mental disorders in UK Biobank-A comparison of approaches. Int J Methods Psychiatr Res. 2019;28(3):e1796-e.

13. Howard DM, Adams MJ, Clarke T-K, Hafferty JD, Gibson J, Shirali M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nature Neuroscience. 2019;22(3):343-52.